AI Revolutionizes Healthcare, Says Science Journalist David Pogue
Artificial intelligence (AI) is increasingly transforming the healthcare landscape, according to science journalist David Pogue. Speaking at the Purdue University Northwest Sinai Forum on October 26, 2025, Pogue highlighted AI’s role in diagnostics, mental health support, and drug development.
Pogue pointed out that AI is now embedded in various aspects of healthcare, stating, “It is in every aspect, every corner of the healthcare system.” He noted that ChatGPT has become the largest provider of mental health support in the United States. During a live demonstration, he simulated a conversation with the chatbot, which offered comforting responses and advice.
An audience member raised a critical question about the responsibilities of mental health chatbots. Pogue affirmed that human therapists are legally obligated to report threats of violence, and he expects similar protocols would apply to AI systems.
Wearable Technology and Health Monitoring
Pogue also discussed the potential of wearable devices such as Apple Watches and Fitbits in preventive healthcare. These gadgets monitor vital signs like heart rate and sleep patterns, providing insights that can alert users to potential health issues. “Now it’s started to warn you about things that might be starting to happen,” he explained, highlighting how these devices can detect anomalies such as atrial fibrillation, a condition that can lead to stroke.
He emphasized that these technologies have likely saved countless lives. “If you know, you can take blood thinners and you won’t get the problem,” Pogue said. He cited recent advancements, including a sleep apnea warning introduced by Apple, and research from Stanford University into how wearables might detect diseases like anemia and even cancer.
Moreover, Pogue shared findings indicating that smartwatches could identify COVID-19 symptoms three days before they appear. This capability could revolutionize early detection and response strategies, enhancing public health measures.
AI in Drug Development
Turning to AI’s impact on pharmaceuticals, Pogue stated that AI has the potential to expedite drug development significantly. “It takes 15 years and billions of dollars to create a new drug,” he noted, explaining why orphan diseases often lack targeted treatments. AI can streamline this process, making it feasible to develop drugs for rare conditions.
He cited an example of a lung disease drug that entered its second round of clinical trials just 13 months after AI identified it. “Suddenly, that’s plausible to do,” he remarked, expressing optimism about AI’s role in tackling severe health issues.
Pogue also referenced research from the Massachusetts Institute of Technology that utilized AI to analyze lung scans from 28,000 patients over five years. The study revealed that AI could predict lung cancer with an accuracy of 95%, showcasing the technology’s potential for early diagnosis of various diseases, including Alzheimer’s.
Despite these advancements, Pogue acknowledged the limitations and challenges associated with AI in healthcare. He pointed out significant data biases, noting that about 80% of electronic health records are from individuals of European descent, which skews AI’s effectiveness for diverse populations.
Concerns about data privacy and consent also surfaced during the discussion. Pogue highlighted that many individuals have not authorized the use of their data, raising ethical questions about accountability in AI-driven decisions.
As he concluded, Pogue expressed a cautious optimism about AI in healthcare. “AI is reshaping the world as we know it. Healthcare is no exception,” remarked Leslie Plesac, Executive Director of the PNW Sinai Forum. With ongoing advancements, the integration of AI promises to enhance diagnostics, treatment options, and patient outcomes, while also necessitating careful consideration of ethical implications.
